PTCT : Summary for PTC Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.16+0.38 (+2.76%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close13.78
Bid13.95 x 800
Ask15.69 x 100
Day's Range13.50 - 14.41
52 Week Range4.03 - 29.98
Avg. Volume781,057
Market Cap483.78M
PE Ratio (TTM)-2.89
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga3 days ago

    Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100

    PTC Therapeutics, Inc. (NASDAQ: PTCT ) shares popped Thursday morning, following a note from Credit Suisse that said the stock could trade up by more than 500 percent.. The predicted activity will depend ...

  • Zacks6 days ago

    Is the Options Market Predicting a Spike in PTC Therapeutics (PTCT) Stock?

    Investors in PTC Therapeutics, Inc. (PTCT) need to pay close attention to the stock based on moves in the options market lately.

  • PR Newswire11 days ago

    PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy

    SOUTH PLAINFIELD, N.J., Feb. 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the third annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates. The patients and organizations have been at the heart of everything we do at PTC and it is particularly rewarding to support programs to further develop new programs to support the Duchenne community around the world," said Mary Frances Harmon, Global Head of Patient Advocacy at PTC.